PinnyPeptide

LL-37 vs TB-500 Fragment 17-23

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

LL-37

Healing & Recovery

Human antimicrobial peptide with broad-spectrum pathogen defense and wound-healing activity.

Peptide B

TB-500 Fragment 17-23

Healing & Recovery

The 7-amino-acid active fragment of TB-500, isolated for cell-migration effects.

Typical vial

5 mg

Typical dose

50-100 mcg

Half-life

~15-30 minutes (rapidly degraded by proteases)

FDA status

Not FDA approved for human use.

Typical vial

10 mg

Typical dose

2000-5000 mcg

Half-life

Estimated minutes to a few hours (much shorter than full TB-500 due to lack of N/C-terminal protection)

FDA status

Not FDA approved for any human or veterinary use. No clinica…

LL-37 effects

  • Broad-spectrum antimicrobial activity against bacteria, fungi, and viruses
  • Disrupts biofilm formation
  • Promotes wound healing and angiogenesis
  • Modulates innate immune responses
  • Neutralizes bacterial endotoxins (LPS)

TB-500 Fragment 17-23 effects

  • Binds G-actin and modulates actin polymerization
  • In vitro promotion of keratinocyte and endothelial cell migration
  • Pro-angiogenic activity in cell-based assays
  • Pro-healing effects on cultured fibroblasts
  • Anti-inflammatory effects (limited to in vitro evidence)
  • Potentially shared but reduced systemic activity vs full TB-500

LL-37 side effects

  • Injection site redness and irritation
  • Potential cytotoxicity at high concentrations
  • Possible mast cell activation
  • Localized skin reactions

TB-500 Fragment 17-23 side effects

  • Injection site irritation or redness
  • Lethargy (anecdotal, mechanism unclear)
  • Mild flu-like symptoms at higher doses (rare)
  • Headache
  • Unknown long-term effects — no human safety data

LL-37 dosing ranges

Antimicrobial support

50-100 mcg · Once daily (SubQ) · 2-4 weeks

Wound healing support

50-100 mcg · Once daily near affected area · 2-4 weeks

TB-500 Fragment 17-23 dosing ranges

Injury recovery (extrapolated)

2-5 mg · Twice weekly SubQ · 4-6 weeks

Tendon/ligament support (extrapolated)

2-5 mg · Twice weekly SubQ · 4-8 weeks

Loading phase (anecdotal)

5 mg · Twice weekly for 2-3 weeks · Then maintenance

LL-37 vs TB-500 Fragment 17-23 — common questions

What is the difference between LL-37 and TB-500 Fragment 17-23?

LL-37: Human antimicrobial peptide with broad-spectrum pathogen defense and wound-healing activity. Typical dose 50-100 mcg. TB-500 Fragment 17-23: The 7-amino-acid active fragment of TB-500, isolated for cell-migration effects. Typical dose 2000-5000 mcg. Both fall under the Healing & Recovery category.

Can you stack LL-37 and TB-500 Fragment 17-23?

Stacking LL-37 with TB-500 Fragment 17-23 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, LL-37 or TB-500 Fragment 17-23?

LL-37 is typically dosed: Once daily (SubQ) for Antimicrobial support; Once daily near affected area for Wound healing support. TB-500 Fragment 17-23 is typically dosed: Twice weekly SubQ for Injury recovery (extrapolated); Twice weekly SubQ for Tendon/ligament support (extrapolated); Twice weekly for 2-3 weeks for Loading phase (anecdotal).

Are LL-37 and TB-500 Fragment 17-23 FDA approved?

LL-37: Not FDA approved for human use. TB-500 Fragment 17-23: Not FDA approved for any human or veterinary use. No clinical trials have been conducted on this specific fragment.

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free